Depression: History and Discovery
For more than two thousand years, the condition we now call depression was known as melancholia — from the Greek melas (black) and cholé (bile) — because Hippocratic medicine taught that an excess of "black bile" weighed down the mind. From Aretaeus of Cappadocia and Galen, through Robert Burton's great 1621 encyclopedia The Anatomy of Melancholy, to the gradual nineteenth-century shift to the Latin-rooted word depression (deprimere, "to press down"), the story is one of a deeply human suffering described again and again, long before anyone could explain it. This page traces that history honestly: it celebrates real discoveries — cognitive therapy, the accidental birth of antidepressants — while being clear about where popular ideas, such as the "chemical imbalance" theory, turned out to be oversimplifications. Depression is a real, treatable medical condition, and its history is the story of how compassion and science slowly learned to take it seriously.
Table of Contents
- Melancholia and the Theory of Black Bile
- Aretaeus, Galen, and the Ancient Physicians
- Robert Burton and The Anatomy of Melancholy (1621)
- From "Melancholia" to "Depression"
- Kraepelin and the Modern Classification
- Somatic Treatments: ECT and the 1930s
- The Accidental Discovery of Antidepressants
- The Monoamine Hypothesis and the "Chemical Imbalance"
- Aaron Beck and Cognitive Therapy
- Research Papers and References
- Connections
Melancholia and the Theory of Black Bile
For most of recorded Western history, depression did not exist under that name. The condition was called melancholia, a word transliterated directly from ancient Greek: melas, meaning "black," joined to cholé, meaning "bile." The name itself is a medical theory in miniature. It comes from the humoral doctrine associated with Hippocrates and his followers around 400 BCE, which held that the body contained four fluids, or humors — blood, phlegm, yellow bile, and black bile — and that health depended on their balance. An excess of cold, dry "black bile" was believed to settle over the mind and produce the heavy, fearful, joyless state the Greeks observed in melancholic patients.
It is worth pausing on how careful these ancient observers were, even with a mistaken mechanism. The Hippocratic writings describe melancholia as a genuine disease with recognizable signs: prolonged fear and despondency that came without obvious cause, loss of appetite, sleeplessness, irritability, and restlessness. One famous aphorism states that "fear or sadness lasting a long time" is the mark of melancholia. Strip away the black bile, and this is a strikingly modern description — persistent low mood, anxiety, and disturbed sleep and appetite are still core to how depression is recognized today.
The black-bile model should be understood as the best hypothesis available to a pre-scientific medicine, not as fact. No such fluid exists; the four humors were never anatomical realities. But the framework had two lasting effects worth remembering. First, it treated melancholia as a bodily illness rather than a moral failing or demonic possession — a comparatively humane stance. Second, it embedded the word so deeply that "melancholy" would dominate medical and literary language for the next two millennia, and its shadow still falls on us whenever depression is imagined as something dark and heavy pressing down from within.
Aretaeus, Galen, and the Ancient Physicians
Two later Greek physicians deepened the classical picture. Aretaeus of Cappadocia, writing in the first century CE, gave some of antiquity's most vivid clinical descriptions of melancholia and is often credited as among the first to observe that melancholia and mania could appear in the same patient — an early glimpse of what we would now call the relationship between depression and bipolar disorder. His accounts emphasize the sufferer's withdrawal, despondency, sleeplessness, and groundless fears, portraying melancholia as a disorder of mood rather than mere sadness.
The towering medical authority of the era was Galen of Pergamon (c. 129–216 CE), whose writings shaped European and Islamic medicine for well over a thousand years. Galen systematized the humoral theory and held firmly that melancholia was caused by an excess or corruption of black bile. He distinguished different sub-types of melancholia and attempted to localize and explain the disorder within the body. Because Galen's authority was so immense, his endorsement of the black-bile explanation effectively locked it into mainstream medicine until the Renaissance and beyond — a reminder of how a single influential framework can outlast the evidence for it.
These ancient texts are named here as historical primary sources, not as modern clinical evidence. Their lasting value is twofold: they show that the core experience of depression has been recognized across cultures and centuries, and they demonstrate how a wrong mechanism (black bile) could nonetheless coexist with sharp, compassionate observation of real human suffering. The continuity of description, even amid changing explanation, is one of the most striking features of depression's long history.
Robert Burton and The Anatomy of Melancholy (1621)
The single greatest landmark in the literature of melancholia is The Anatomy of Melancholy, first published in 1621 by Robert Burton (1577–1640), an Oxford scholar and clergyman. Sprawling, digressive, and endlessly revised by its author across later editions, the book has been called the first true encyclopedia of psychiatry. Burton set out to anatomize melancholy in every dimension — its causes, symptoms, varieties, and cures — drawing on classical medicine, theology, philosophy, and his own painful experience of the condition he described.
What makes Burton remarkable, and why he is still read four hundred years later, is how modern much of his counsel sounds. Alongside the inherited humoral framework, he recommended remedies that anticipate today's lifestyle and behavioral approaches: regular physical activity, good diet, music, satisfying work and occupation of the mind, companionship, and the avoidance of idleness and solitude. His famous practical advice — to be "not idle" and not to be alone — reads as an early, intuitive grasp of behavioral activation and social connection as antidotes to depression.
Burton wrote in an age that still lacked any biological understanding of the brain, so his explanatory model remains pre-scientific. But The Anatomy of Melancholy matters as a cultural and clinical turning point: it gathered two thousand years of thought about the condition into one humane, exhaustive volume, treated melancholy as a serious and widespread affliction deserving careful study, and insisted that sufferers could be helped. For a person living centuries before antidepressants or therapy, that message — that melancholy is real, common, and not hopeless — was itself a form of comfort.
From "Melancholia" to "Depression"
The word depression arrived only gradually, and from outside medicine. It derives from the Latin verb deprimere, "to press down," and for centuries it carried general meanings of lowering or pushing down — a depression in the ground, a fall in economic activity, a sinking of the spirits. From around the fourteenth century, "to depress" could mean to subjugate or to bring down in spirit, but this was metaphor, not diagnosis.
The clinical use emerged in the nineteenth century. The French psychiatrist Louis Delasiauve is often cited for an early psychiatric use of the term around 1856, and by the 1860s "depression" was appearing in medical dictionaries to describe a lowering of emotional and physiological function. Over the following decades, "depression" steadily encroached on the older, broader word "melancholia," which had accumulated centuries of literary and humoral baggage. The Swiss-American psychiatrist Adolf Meyer, an enormously influential figure in early twentieth-century American psychiatry, explicitly argued that "depression" should be used in place of "melancholia," favoring a term less tied to discredited humoral theory.
This shift in vocabulary was not merely cosmetic. Moving from "melancholia" to "depression" helped detach the condition from the black-bile model and reframed it as a definable lowering of mood and function that could, in principle, be studied scientifically. The change tracks a larger nineteenth-century transformation in which mental suffering was increasingly approached as medicine and emerging psychology rather than as humoral imbalance or moral state. The new name carried, embedded in its Latin root, the same ancient intuition the Greeks had voiced: that this is an experience of being pressed down.
Kraepelin and the Modern Classification
The framework that organizes how depression is diagnosed today owes much to the German psychiatrist Emil Kraepelin (1856–1926). Through successive editions of his influential Textbook of Psychiatry at the turn of the twentieth century, Kraepelin worked to classify mental disorders by their patterns, course, and outcome rather than by single symptoms. In the sixth edition (1899) he gave the name "manic-depressive insanity" (manisch-depressives Irresein) to a broad category encompassing the major mood disorders — the episodes of depression and of mania that French "alienists" earlier in the nineteenth century had already described as a "circular" or alternating illness.
Kraepelin's great contribution was the separation of the mood disorders from the chronic psychotic disorders. He drew a now-famous distinction between "manic-depressive insanity," which tended to run in episodes with relatively good recovery between them, and dementia praecox (later renamed schizophrenia), which he saw as following a more deteriorating course. This division — mood disorders on one side, schizophrenia on the other — remains a load-bearing wall of modern psychiatric classification.
Over the twentieth century, Kraepelin's sweeping "manic-depressive" category was gradually subdivided. The conditions we now call major depressive disorder and bipolar disorder were eventually distinguished and codified in the classification systems used today, such as the DSM and ICD. But the underlying Kraepelinian logic — that depression is a definable disorder, that it can be recognized by its course, and that it sits in a meaningful relationship to mania — runs straight through to the contemporary clinic.
Somatic Treatments: ECT and the 1930s
The 1930s saw the first physical, or "somatic," treatments aimed directly at the brain in severe mental illness. The most enduring of these was electroconvulsive therapy (ECT), developed by the Italian neuropsychiatrists Ugo Cerletti and Lucio Bini. The first application of electrically induced therapeutic seizure to a human patient took place at the University of Rome in 1938 (the first treatment is dated to 11 April 1938). The technique grew out of a then-current belief that induced seizures might relieve symptoms in severe psychiatric illness, and it was first used in a patient with psychosis.
Early ECT was crude and frightening by modern standards: it was administered without anesthesia or muscle relaxants, and the convulsions it produced could cause injuries. Its disturbing portrayal in mid-century films and books left a lasting stigma. It is honest to acknowledge this history rather than gloss over it, because that legacy still shapes how many people feel about the treatment.
At the same time, it would be inaccurate to leave ECT in the past tense. Modern ECT is performed under general anesthesia with muscle relaxants and careful monitoring, and contemporary clinical guidelines recognize it as one of the most effective treatments available for severe, treatment-resistant, or life-threatening depression, including depression with strong suicidal risk or with psychotic features. The historical point is that the 1930s marked the moment medicine began intervening directly in the biology of severe depression — imperfectly at first, but in ways that, much refined, still save lives.
The Accidental Discovery of Antidepressants
One of the most important facts in the history of depression is that the first antidepressant drugs were discovered largely by accident — serendipity, not theory, opened the modern pharmacological era. In the early 1950s, doctors testing the drug iproniazid as a treatment for tuberculosis noticed an unexpected side effect: some patients became unusually cheerful, energetic, and elevated in mood. Iproniazid worked by inhibiting an enzyme called monoamine oxidase, making it the first of the monoamine oxidase inhibitors (MAOIs), and its mood-lifting effect was the clue that a chemical could relieve depression.
At nearly the same time, the Swiss psychiatrist Roland Kuhn, working with the compound imipramine, made a parallel discovery. Imipramine had been investigated as a possible treatment for schizophrenia and was a disappointment there — but Kuhn observed that it noticeably lifted mood in depressed patients. Imipramine became the first of the tricyclic antidepressants (TCAs). So within roughly the same span of the mid-1950s, two different drugs, each developed for an entirely unrelated illness, were both found to treat depression.
The historical sequence here matters and is often misremembered. The drugs came first; the biochemical theory of depression came afterward, in part as an attempt to explain why these accidental medicines worked. Researchers asked what iproniazid and imipramine had in common and found that both, in different ways, increased the availability of monoamine neurotransmitters — chemicals such as norepinephrine and serotonin — in the brain. That observation became the seed of the monoamine hypothesis, the subject of the next section, and a cautionary example of how a treatment's mechanism can be inferred backward and then over-interpreted.
The Monoamine Hypothesis and the "Chemical Imbalance"
In 1965, the American psychiatrist Joseph Schildkraut published an influential review proposing what became known as the catecholamine (monoamine) hypothesis of depression: the idea that depression might be associated with a deficiency of monoamine neurotransmitters, particularly norepinephrine, in the brain. As serotonin-focused research and drugs developed, the hypothesis broadened to include serotonin and gave rise to the popular shorthand that depression is caused by a "chemical imbalance." When selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine reached the market from the late 1980s, the serotonin version of the theory became enormously well known, reinforced by widespread advertising.
It is essential to be honest that the monoamine theory was, and remains, a hypothesis — and one that the field now regards as, at best, a major oversimplification. Even Schildkraut himself, in 1965, cautioned that the available evidence did not allow the hypothesis to be confirmed or rejected. Crucially, the simple "low serotonin causes depression" story has not held up. A widely discussed 2022 systematic umbrella review led by Joanna Moncrieff and colleagues, published in Molecular Psychiatry, concluded that there is no consistent evidence that depression is caused by low serotonin or by a serotonin abnormality. In plain terms: the popular "chemical imbalance" explanation is not supported by the evidence as a complete account of depression.
Two cautions keep this fair and useful. First, the 2022 review was itself contested: a number of researchers argued that its methods and conclusions were too sweeping, and the scientific debate continues — so it is most accurate to say the simple serotonin theory is discredited, while the full biology of depression remains an open question involving many brain systems, stress, genetics, inflammation, and life circumstances. Second, and very importantly, the fact that the chemical-imbalance story is an oversimplification does not mean antidepressants do not help. Many people benefit from these medicines even though why they work is more complex than a single missing chemical. No one should stop an antidepressant based on this history; medication changes should always be discussed with a prescriber, ideally with a gradual, supervised taper. Today depression is best understood as a real condition arising from many interacting causes — biological, psychological, and social — not as one broken molecule.
Aaron Beck and Cognitive Therapy
While the drug story unfolded, an equally consequential revolution was taking place in psychotherapy. In the early 1960s, the American psychiatrist Aaron T. Beck (1921–2021), then at the University of Pennsylvania, was studying depression from within the psychoanalytic tradition. As he listened to depressed patients, he noticed something his training had not prepared him for: a steady stream of automatic, negative thoughts about themselves, the world, and the future. He came to describe this as the "cognitive triad" of depression — a negative view of the self, of experience, and of what lies ahead.
From this observation Beck built cognitive therapy (later broadened into cognitive behavioral therapy, or CBT). Rather than excavating the distant past, the approach helped patients identify, examine, and test their distorted automatic thoughts in the present, replacing catastrophic or self-condemning interpretations with more accurate and balanced ones. It was structured, collaborative, time-limited, and — importantly for science — teachable and measurable. A landmark moment came in 1977, when a major clinical trial reported that cognitive therapy performed at least as well as antidepressant medication for depression, making it one of the first "talking therapies" shown in a rigorous trial to rival drugs.
Beck's legacy reframed depression as something a person could actively work to change, not merely endure or medicate. CBT and its descendants are now among the most thoroughly studied and widely recommended treatments for depression worldwide, often used alongside or instead of medication. Together with the lessons of the antidepressant and serotonin story, Beck's work points to the modern, honest consensus: depression is real and treatable, multiple effective treatments exist — psychological, pharmacological, and social — and care works best when it is matched to the whole person rather than to any single theory of cause.
Research Papers and References
The references below combine key peer-reviewed and authoritative sources on the history and science of depression with curated PubMed topic-search links. Historical primary texts — the Hippocratic writings, Galen, Aretaeus of Cappadocia, and Robert Burton's The Anatomy of Melancholy (1621) — are named in the article as historical sources rather than as modern citations. Each link opens in a new tab.
- Telles-Correia D, Marques JG. Melancholia before the twentieth century: fear and sorrow or partial insanity? Frontiers in Psychology. 2015;6:81. — doi:10.3389/fpsyg.2015.00081
- Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. American Journal of Psychiatry. 1965;122(5):509-522. — doi:10.1176/ajp.122.5.509
- Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Molecular Psychiatry. 2023;28(8):3243-3256. — doi:10.1038/s41380-022-01661-0
- Lacasse JR, Leo J. Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Medicine. 2005;2(12):e392. — doi:10.1371/journal.pmed.0020392
- Hirschfeld RMA. History and evolution of the monoamine hypothesis of depression. Journal of Clinical Psychiatry. 2000;61(Suppl 6):4-6. — PubMed: 10775017
- Hippocrates, Galen, and the humoral theory of melancholia (historical review) — PubMed: melancholia black bile humoral theory history
- Aretaeus of Cappadocia and the early concept of melancholia and mania — PubMed: Aretaeus of Cappadocia melancholia mania
- Radden J. Robert Burton's Anatomy of Melancholy and the history of depression — PubMed: Burton Anatomy of Melancholy depression history
- Kraepelin and the concept of manic-depressive insanity: an historical perspective — PubMed: 16194770
- History of the term "depression" and its replacement of "melancholia" — PubMed: history of the concept of depression and melancholia
- Cerletti and Bini and the origins of electroconvulsive therapy (1938) — PubMed: 11940939 (origins of ECT)
- Serendipity and the discovery of iproniazid and imipramine, the first antidepressants — PubMed: iproniazid imipramine history of antidepressants
- Beck AT and the development of cognitive therapy for depression — PubMed: Beck cognitive therapy depression history
- Cuijpers P, et al. Cognitive behavior therapy versus antidepressant medication for depression (comparative efficacy) — PubMed: CBT versus antidepressant medication for depression
External Authoritative Resources
- NIMH — Depression (National Institute of Mental Health)
- World Health Organization — Depressive Disorder Fact Sheet
- PubMed — History of depression and melancholia